DEEP RESEARCH · LIGACHEM BIOSCIENCES/ADC
LigaChem Biosciences: ADC Platform Value and the Global Clinical Inflection
A review of ConjuALL™ technology, KRW 558.9B in practical liquidity, KRW 8T-scale licensing, and the LCB84 option event.
0. Bottom line first
My core view is that LigaChem is moving from a validated ADC platform provider into a global drug developer with internal clinical capability and royalty potential. At Q3 2025, practical liquidity was about KRW 558.9B, the debt ratio was about 24.2%, and cumulative licensing value was described as more than KRW 8T, or 8.3 billion USD.
Cash runway secured
Cash and equivalents of KRW 153.5B plus other current financial assets of KRW 405.4B make practical liquidity about KRW 558.9B.
Globally validated
Deals with Janssen, Ono, Amgen, Iksuda, Fosun, and CStone form a KRW 8T-scale licensing reference base.
LCB84 option
Janssen’s sole-development option fee of $200M, about KRW 260B, is presented as the key 2025 event.
1. Position in the ADC market
The global pharma and biotech industry is riding a major antibody-drug conjugate, or ADC, wave. After Enhertu’s commercial success, the guided-missile concept is reshaping cancer standards of care by addressing systemic toxicity from chemotherapy and resistance in targeted therapies.
Official fact: The source analyzes LigaChem’s financial position, licensing contracts, pipeline roadmap, and market outlook using the Q3 2025 quarterly report and the Q4 2024 corporate presentation. It also includes an attached LigaChem analysis MP3.
Interpretation: LigaChem is not only supplying the ConjuALL™ platform. Through co-development and internal pipelines, it is entering a stage where the market can re-rate it as a drug developer.
2. Financial strength: can it fund planned losses?
Official fact: At Q3 2025, current assets were KRW 595,605,314,710, cash and cash equivalents were KRW 153,497,846,805, and other current financial assets were KRW 405,409,874,433. Total assets were KRW 699,431,321,814 and the debt ratio was about 24.2%.
| Item | Q3 2025 end | 2024 end | Meaning |
|---|---|---|---|
| Current assets | KRW 595,605,314,710 | KRW 550,261,759,025 | Up about 8.2% |
| Cash and equivalents | KRW 153,497,846,805 | KRW 128,912,155,244 | Immediately available cash increased |
| Other current financial assets | KRW 405,409,874,433 | KRW 397,422,388,970 | Deposits and cash-like assets |
| Total assets | KRW 699,431,321,814 | KRW 738,382,908,190 | Maintained around KRW 700B |
| Debt ratio | About 24.2% | About 19.9% | Still low leverage |
Interpretation: Practical liquidity of KRW 558.9B gives enough runway to develop multiple assets such as LCB84 and LCB71 over the next three to four years without urgent financing. Orion Group’s roughly KRW 470B paid-in capital increase in 2024 removed a major financial uncertainty.
Official fact: Q3 2025 cumulative revenue was KRW 125,602,208,017. Licensing revenue was KRW 110,097,827,000, or 87.7%, while product revenue was KRW 15,504,381,000, or 12.3%. R&D expense was KRW 134,483,434,011, or 107% of revenue. Operating loss was KRW 33,367,977,592 and net loss was KRW 26,950,008,659.
| Income item | Amount | Interpretation |
|---|---|---|
| Revenue | KRW 125,602,208,017 | Driven by licensing revenue |
| Licensing revenue | KRW 110,097,827,000 | 87.7% of revenue |
| Product revenue | KRW 15,504,381,000 | Medical device/consumables cash cow |
| R&D expense | KRW 134,483,434,011 | 107% of revenue and about 84.6% of operating expense |
| Operating loss | KRW 33,367,977,592 | Planned loss from global clinical expansion |
Interpretation: Janssen’s $100M upfront, about KRW 130B, is recognized over the contract period and provides a stable revenue base. The operating loss is better read as a growth-stage, R&D-heavy loss driven by CRO and sample-production costs, not as evidence of business distress.
3. Licensing contracts: validation matters more than headline value
LigaChem has achieved cumulative licensing value of roughly KRW 8T, or more than 8.3 billion USD. These deals are not only totals; they are references showing that global pharma partners passed the platform through due diligence.
| Partner | Asset | Date | Total deal value | Stage and point |
|---|---|---|---|---|
| Janssen | LCB84, TROP2-ADC | 2023.12 | About KRW 2.2458T, $1.7B | $100M upfront and $200M additional option fee |
| Ono Pharma | LCB97, L1CAM-ADC | 2024.10 | About KRW 943.5B, $700M | Preclinical asset; IND and early milestones expected |
| Ono Pharma | ADC platform, multi-target | 2024.10 | Undisclosed | Additional payments when targets are selected |
| Amgen | ADC platform, five targets | 2022.12 | About KRW 1.605T, $1.25B | Milestones as candidates are generated |
| Iksuda | LCB14, HER2-ADC | 2021.12 | About KRW 1.1864T, $1B | Global rights excluding China/Korea; global Phase 1 |
| Fosun Pharma | LCB14, HER2-ADC | 2015.08 | About KRW 20.8B + royalty | China Phase 3; royalty potential after 2026 |
| CStone | LCB71, ROR1-ADC | 2020.10 | About KRW 409.9B, $363.5M | Global Phase 1; milestone on Phase 2 entry |
The Janssen LCB84 deal is the quantum-jump trigger. If positive Phase 1 data leads Janssen to exercise its option, $200M, about KRW 260B, could come in and lift cash holdings toward the KRW 800B level, according to the source’s estimate.
Interpretation: The Ono deal matters because it combined a product and a platform. If the platform is repeatedly used like an operating system for ADC development, new target selection can create recurring upfronts and milestones.
4. Technology moat: three pillars of ConjuALL™
Site-specific conjugation
Drug payloads are attached to specific antibody sites, producing a uniform DAR, usually 2 or 4, and improving manufacturing control.
LBG linker
The linker is stable in blood and cleaved by beta-glucuronidase in tumor-cell lysosomes, reducing off-target toxicity.
PBD prodrug
A potent PBD payload is carried in an inactive prodrug form and activated only after reaching target cells.
Official fact: The source contrasts LigaChem’s technology with first-generation ADCs that use random conjugation and produce uneven DAR, and argues that LigaChem’s approach supports predictable PK and high purity.
Interpretation: In ADCs, safety and manufacturing quality are as important as efficacy. LigaChem’s differentiation is how precisely, stably, and reproducibly it delivers a highly potent payload.
5. Pipeline roadmap
| Project | Target | Partner | Current stage | Expected milestone |
|---|---|---|---|---|
| LCB14 | HER2 | Fosun, Iksuda | China Phase 3 / global Phase 1 | China NDA in 2025 and sales royalties expected from 2026 |
| LCB84 | TROP2 | Janssen | US Phase 1/2 | Phase 1 data in 2025 and possible $200M option exercise |
| LCB71 | ROR1 | CStone | Global Phase 1 | Milestone on Phase 2 entry |
| LCB97 | L1CAM | Ono Pharma | Preclinical | IND and Phase 1 in 2025~2026 |
| LCB41A | B7-H4 | Internal | Preclinical | Phase 1 target in H1 2025 |
| LCB39 | STING agonist | Internal | Preclinical | Phase 1 target in 2026 |
- LCB14 is in China Phase 3 for breast cancer and Phase 2 for gastric cancer through Fosun, while Iksuda is running global Phase 1 studies in markets such as the US and Australia. The source highlights potential improvement versus Enhertu on ILD and ocular-toxicity issues in ASCO 2024 data.
- LCB84 is a TROP2-ADC competing with Trodelvy and Dato-DXd. Its ADAM10-cleavable linker is the mechanistic differentiator and may open activity in tumors with lower TROP2 expression.
- LCB71 combines a ROR1 target with PBD prodrug technology and is being watched for expansion across hematologic and solid tumors.
6. Market outlook, risks, and my conclusion
Official fact: The source expects the global ADC market to grow from about $10B in 2023 to about $45.9B, or roughly KRW 60T, by 2030, implying more than 27% annual growth.
Risk factors
- Competition with Daiichi Sankyo, Pfizer/Seagen, AbbVie, and other global giants is intensifying.
- Partner commitment changes, weak clinical data, and milestone delays remain core drug-development risks.
My watch points
- LCB84 data in 2025 and whether Janssen exercises the option
- LCB14 China NDA, commercialization in 2026, and royalty generation
- Whether the Ono-style package deal repeats with additional major pharma partners
Interpretation: LigaChem has moved beyond pure technology validation and is entering the front end of commercial realization. The next two to three years will determine whether it can become a global top-tier biotech.
Sources
- Original Naver Blog post: https://m.blog.naver.com/PostView.naver?blogId=star_of_self&logNo=224090319494
- Attached MP3: https://download.blog.naver.com/open/d540c972605e5febc02e40764caad0a80e59a273/EFsQaLZLxrjO9dg2E-QRigSVEg-Y7dtnemsQLWUj_gMvH468Vn4l5Pm5C4gOzC1M0y_0blrvu0pwwr-XMwmnZN_u8HrTzPU/%EB%A6%AC%EA%B0%80%EC%BC%90%EB%B0%94%EC%9D%B4%EC%98%A4%EC%9D%98%20%EC%A7%84%EC%A7%9C%20%EB%AC%B4%EA%B8%B0%20%ED%80%80%ED%85%80%20%EC%A0%90%ED%94%84%20%EB%B3%80%EA%B3%A1%EC%A0%90%20%EB%B6%84%EC%84%9D.mp3